EKF Diagnostics Holdings PLC Posting of AR & Accounts and Notice of AGM (0159X)

TIDMEKF

RNS Number : 0159X

EKF Diagnostics Holdings PLC

25 April 2019

EKF Diagnostics Holdings plc

("EKF", the "Company")

Posting of Annual Report & Accounts and Notice of AGM

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that the Annual Report and Accounts for the year ended 31 December 2018 ("2018 Annual Report") and the Notice of the Annual General Meeting contained therein (the "Notice of AGM") are available on the Company's website:

https://www.ekfdiagnostics.com/hres/Annual-report-2018-Digital.pdf

The 2018 Annual Report, the Notice of AGM and forms of proxy were posted to shareholders on the 8 April 2019. Shareholders were also sent an accompanying letter requesting agreement for the Company to use electronic communication to provide documents and information to them via the EKF website, together with a copy of the amended Articles of Association to enable this, subject to the passing of the relevant resolution to be put to shareholders at the AGM.

The AGM is to be held on 2 May 2019 at 11am at the offices of Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD.

Enquiries:

 
     EKF Diagnostics Holdings plc                            www.ekfdiagnostics.com 
     Christopher Mills, Non-Executive Chairman                   Tel: [phone] 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
 
     N+1 Singer (Nomad & Broker)                                 Tel: [phone] 
     Aubrey Powell / Lauren Kettle / George Tzimas 
      (Corporate Finance) 
      Tom Salvesen (Corporate Broking) 
 
     Walbrook PR Limited Tel: [phone] or [e-mail] 
     Paul McManus/ Lianne Cawthorne                      Mob: [phone] / 07584 
                                                                            391 303 
 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCCKQDDCBKDDQB

(END) Dow Jones Newswires

April 25, 2019 02:00 ET (06:00 GMT)